

LINCOLN
PHARMACEUTICALS LTD.
HEALTHCARE FOR ALL

Date: 11th August, 2016

To, The Manager, Listing Department, National Stock Exchange of India Limited, Exchange Plaza, C-1, Block-G, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 051.	To, The Department of Corporate Service, Bombay Stock Exchange Limited, Phirozejeebhoy Tower, Dalal Street, Mumbai - 400 001.	To, The Secretary, Ahmedabad Stock Exchange Limited, Kamdhenu Complex, Opp. Sahjanand College, Nr. Polytechnic, Panjarapole, Ahmedabad - 380 015.
Scrip Code - LINCOLN	Scrip Code - 531633	Scrip Code - 32428

Dear Sir,

SUB.: OUTCOME OF BOARD MEETING.

With reference to the above, we would like to inform that the following is the outcome of the meeting of the Board of Directors of the Company held on Thursday, 11th August, 2016:

1. The quarterly un-audited standalone & consolidated financial results for the quarter ended on 30th June, 2016.
2. Limited Review Report in the prescribed format from Statutory Auditors M/s. J. T. Shah & Co., on standalone & consolidated financial results for the quarter ended on 30th June, 2016.

The meeting of the Board of Directors of the Company commenced at 10.00 A.M. and concluded at 11.10 A.M.

Kindly acknowledge the receipt of the same.

Thanking you,

Yours faithfully,

FOR LINCOLN PHARMACEUTICALS LIMITED


(DIRECTOR / AUTHORISED SIGNATORY)



Encl: As above

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India

Phone : +91-79-6777 8000 | Fax : +91-79-6777 8062

E-mail : info@lincolnpharma.com | Website : www.lincolnpharma.com

CIN : L24230GJ1995PLC024288

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721. Ta. : Kalol, Dist. Gandhinagar, (Guj.)

Phone : 02764-665000

E-mail : khatraj@lincolnpharma.com / lincoln_khatraj@rediffmail.com





LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" B/h. Satyam Complex, Science City Road, Sola, Ahmedabad - 380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-67778000, Fax: +91-79-6777 8062

Website: www.lincolnpharma.com, E-Mail: info@lincolnpharma.com



LINCOLN
PHARMACEUTICALS LTD.
HEALTHCARE FOR ALL

LINCOLN
PHARMACEUTICALS LTD.
HEALTHCARE FOR ALL

PART-I

Statement of Consolidated and Standalone Unaudited Results for the Quarter ended on 30/06/2016

(Rs. In Lacs)

Sr. No.	Particulars	Consolidated				Standalone			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		30/06/2016 (Unaudited)	31/03/2016 (Audited)	30/06/2015 (Unaudited)	31/03/2016 (Audited)	30/06/2016 (Unaudited)	31/03/2016 (Audited)	30/06/2015 (Unaudited)	31/03/2016 (Audited)
1	Income from Operations								
(a)	Net Sales/Income from Operations (Net of excise duty)	8,916.27	11,998.62	7,323.41	38,889.78	7,611.08	8,689.26	5,844.39	29,955.86
(b)	Other Operating Income	352.57	852.46	245.03	1,861.29	342.82	799.32	222.90	1,754.32
	Total income from Operations (net)	9,268.84	12,851.08	7,568.44	40,751.07	7,953.90	9,488.58	6,067.29	31,710.18
2	Expenses								
(a)	Cost of Materials consumed	1,807.57	2,005.65	1,454.58	7,178.70	1,388.08	1,569.18	1,125.60	5,578.37
(b)	Purchase of stock-in-trade	2,626.63	7,148.31	3,508.41	21,010.98	2,091.84	4,691.46	2,600.84	15,225.87
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	645.38	209.64	-359.37	-444.55	644.36	187.66	-272.77	-438.89
(d)	Employee benefits expense	1,258.53	955.34	819.95	3,527.01	1,144.19	898.34	770.93	3,317.34
(e)	Depreciation and amortisation expense	138.11	128.78	114.04	483.97	96.11	89.64	72.04	318.83
(f)	Other expenses	1,125.48	1,379.62	1,000.43	4,692.21	1,077.40	1,224.17	853.65	4,149.22
	Total Expenses	7,601.70	11,827.34	6,538.04	36,448.32	6,441.98	8,660.45	5,150.29	28,150.74
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	1,667.14	1,023.74	1,030.40	4,302.75	1,511.92	828.13	917.00	3,559.44
4	Other Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	1,667.14	1,023.74	1,030.40	4,302.75	1,511.92	828.13	917.00	3,559.44
6	Finance Costs	211.04	408.39	198.90	996.19	163.12	106.72	150.74	553.73
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	1,456.10	615.35	831.50	3,306.56	1,348.80	721.41	766.26	3,005.71
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	1,456.10	615.35	831.50	3,306.56	1,348.80	721.41	766.26	3,005.71
10	Tax expense	361.84	206.19	176.96	926.58	333.31	211.71	157.96	831.10
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	1,094.26	409.16	654.54	2,379.98	1,015.49	509.70	608.30	2,174.61
12	Extraordinary items (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11 + 12)	1,094.26	409.16	654.54	2,379.98	1,015.49	509.70	608.30	2,174.61
14	Share of Profit / (loss) of associates *	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority Interest	1.11	7.39	0.66	11.74	0.00	0.00	0.00	0.00
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15)*	1,093.15	401.77	653.88	2,368.24	1,015.49	509.70	608.30	2,174.61
17	Paid-up equity share capital of face value Rs.10/- each	1,631.08	1,631.08	1,631.08	1,631.08	1,631.08	1,631.08	1,631.08	1,631.08
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-----	-----	-----	11,589.75	-----	-----	-----	11,481.83
19 i & ii.	Earnings Per Share (before and after extraordinary items) (of Rs. 10/- each) (not annualised):								
	Basic	6.70	2.46	4.01	14.52	6.23	3.12	3.73	13.33
	Earnings Per Share (before and after extraordinary items) (of Rs. 10/- each) (not annualised):								
	Diluted	6.70	2.40	4.01	14.16	6.23	3.05	3.73	13.01

Notes:

- The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Company at the meeting held on 11th August, 2016.
- Figures for the previous periods/year are being regrouped wherever necessary.
- Since the revenue from different segment is less than 10% of total revenue, segment wise results are not given.
- Statutory Auditors has carried out limited review for the quarterly result for quarter ended 30.06.2016
- Consolidated results includes results of it subsidiary Company.

Place: Ahmedabad
Date: 11/08/2016



FOR LINCOLN PHARMACEUTICALS LIMITED

M. G. Patel
(MAHENDRA G. PATEL)
MANAGING DIRECTOR
[DIN: 00104706]

J. T. SHAH & CO.

CHARTERED ACCOUNTANTS

To
Board of Directors of
Lincoln Pharmaceuticals Limited
Ahmedabad.


We have reviewed the accompanying statement of unaudited Standalone financial results of **Lincoln Pharmaceuticals Limited** having its Registered Office at 'Lincoln House', Science City Road, Sola, Ahmedabad-380060, Gujarat for the quarter ended on 30/06/2016 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors which has been prepared in accordance with applicable accounting standards specified under Section 133 of Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting policies generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards specified under Section 133 of Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 11/08/2016
Place: Ahmedabad

For, J. T. Shah & Co.
Chartered Accountants
(FRN No. 109616W)



(J. T. Shah)
Partner
[M.No.3983]

J. T. SHAH & CO.

CHARTERED ACCOUNTANTS

To
Board of Directors of
Lincoln Pharmaceuticals Limited
Ahmedabad.

We have reviewed the accompanying statement of unaudited **Consolidated financial** results of **Lincoln Pharmaceuticals Limited** having its Registered Office at 'Lincoln House', Science City Road, Sola, Ahmedabad-380060, Gujarat for the quarter ended on 30/06/2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors which has been prepared in accordance with applicable accounting standards specified under Section 133 of Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting policies generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We did not review the financial statements of subsidiaries included in consolidated unaudited financial statement, whose consolidated unaudited financial statements reflect the total revenue of Rs.1717.58 Lacs and net profit of Rs.78.76 Lacs for the quarter ended on 30/06/2016. These financial results and other financial information have been reviewed by other auditors whose report has been furnished to us, and our conclusion, to the extent they have been derived from such interim financial statements is based solely on the report of such other auditors.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards specified under Section 133 of Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, J. T. Shah & Co.
Chartered Accountants
(FRN No. 109616W)



J. T. Shah
(J. T. Shah)
Partner

[M.No.3983]

Date: 11/08/2016
Place: Ahmedabad